vs
永明金融（CFFI）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
永明金融的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.0倍（$35.9M vs $35.5M），永明金融净利率更高（18.7% vs -304.2%，领先322.9%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 12.0%），永明金融自由现金流更多（$22.2M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 8.2%）
永明金融是一家总部位于加拿大安大略省多伦多市的金融服务公司，创立于1865年，业务遍及全球，主要提供人寿保险、财富管理以及资产管理服务。截至2024年，公司管理资产规模超过1.3万亿加元，服务网络覆盖加拿大、美国、亚洲及多个其他市场。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CFFI vs RXRX — 直观对比
营收规模更大
CFFI
是对方的1.0倍
$35.5M
营收增速更快
RXRX
高出669.8%
12.0%
净利率更高
CFFI
高出322.9%
-304.2%
自由现金流更多
CFFI
多$69.5M
$-47.3M
两年增速更快
RXRX
近两年复合增速
8.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $35.9M | $35.5M |
| 净利润 | $6.7M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 22.6% | -304.8% |
| 净利率 | 18.7% | -304.2% |
| 营收同比 | 12.0% | 681.7% |
| 净利润同比 | 11.0% | 39.6% |
| 每股收益（稀释后） | $2.08 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CFFIRXRX
| Q4 25 | $35.9M | $35.5M | ||
| Q3 25 | $36.0M | $5.2M | ||
| Q2 25 | $36.4M | $19.2M | ||
| Q1 25 | $32.6M | $14.7M | ||
| Q4 24 | $32.0M | $4.5M | ||
| Q3 24 | $33.5M | $26.1M | ||
| Q2 24 | $31.2M | $14.4M | ||
| Q1 24 | $30.6M | $13.8M |
净利润CFFIRXRX
| Q4 25 | $6.7M | $-108.1M | ||
| Q3 25 | $7.1M | $-162.3M | ||
| Q2 25 | $7.7M | $-171.9M | ||
| Q1 25 | $5.4M | $-202.5M | ||
| Q4 24 | $6.0M | $-178.9M | ||
| Q3 24 | $5.4M | $-95.8M | ||
| Q2 24 | $5.0M | $-97.5M | ||
| Q1 24 | $3.4M | $-91.4M |
毛利率CFFIRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率CFFIRXRX
| Q4 25 | 22.6% | -304.8% | ||
| Q3 25 | 24.5% | -3327.6% | ||
| Q2 25 | 26.5% | -916.8% | ||
| Q1 25 | 20.0% | -1297.9% | ||
| Q4 24 | 22.6% | -4042.4% | ||
| Q3 24 | 19.9% | -377.1% | ||
| Q2 24 | 20.0% | -697.4% | ||
| Q1 24 | 13.1% | -698.4% |
净利率CFFIRXRX
| Q4 25 | 18.7% | -304.2% | ||
| Q3 25 | 19.6% | -3135.3% | ||
| Q2 25 | 21.2% | -894.2% | ||
| Q1 25 | 16.5% | -1373.3% | ||
| Q4 24 | 18.8% | -3935.5% | ||
| Q3 24 | 16.1% | -367.5% | ||
| Q2 24 | 16.1% | -676.6% | ||
| Q1 24 | 11.1% | -662.4% |
每股收益（稀释后）CFFIRXRX
| Q4 25 | $2.08 | $-0.17 | ||
| Q3 25 | $2.18 | $-0.36 | ||
| Q2 25 | $2.37 | $-0.41 | ||
| Q1 25 | $1.66 | $-0.50 | ||
| Q4 24 | $1.85 | $-0.56 | ||
| Q3 24 | $1.65 | $-0.34 | ||
| Q2 24 | $1.50 | $-0.40 | ||
| Q1 24 | $1.01 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $261.8M | $1.1B |
| 总资产 | $2.8B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资CFFIRXRX
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
总债务CFFIRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益CFFIRXRX
| Q4 25 | $261.8M | $1.1B | ||
| Q3 25 | $253.3M | $1.0B | ||
| Q2 25 | $240.3M | $919.1M | ||
| Q1 25 | $234.6M | $933.9M | ||
| Q4 24 | $226.4M | $1.0B | ||
| Q3 24 | $227.3M | $524.6M | ||
| Q2 24 | $218.5M | $584.4M | ||
| Q1 24 | $216.3M | $401.2M |
总资产CFFIRXRX
| Q4 25 | $2.8B | $1.5B | ||
| Q3 25 | $2.7B | $1.4B | ||
| Q2 25 | $2.7B | $1.3B | ||
| Q1 25 | $2.6B | $1.3B | ||
| Q4 24 | $2.6B | $1.4B | ||
| Q3 24 | $2.6B | $726.5M | ||
| Q2 24 | $2.5B | $775.9M | ||
| Q1 24 | $2.5B | $557.8M |
负债/权益比CFFIRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $24.5M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $22.2M | $-47.3M |
| 自由现金流率自由现金流/营收 | 61.8% | -133.1% |
| 资本支出强度资本支出/营收 | 6.5% | 3.5% |
| 现金转化率经营现金流/净利润 | 3.65× | — |
| 过去12个月自由现金流最近4个季度 | $42.8M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流CFFIRXRX
| Q4 25 | $24.5M | $-46.1M | ||
| Q3 25 | $23.4M | $-117.4M | ||
| Q2 25 | $-4.4M | $-76.4M | ||
| Q1 25 | $3.2M | $-132.0M | ||
| Q4 24 | $36.8M | $-115.4M | ||
| Q3 24 | $404.0K | $-59.2M | ||
| Q2 24 | $1.7M | $-82.2M | ||
| Q1 24 | $895.0K | $-102.3M |
自由现金流CFFIRXRX
| Q4 25 | $22.2M | $-47.3M | ||
| Q3 25 | $22.7M | $-117.6M | ||
| Q2 25 | $-5.0M | $-79.6M | ||
| Q1 25 | $2.9M | $-133.8M | ||
| Q4 24 | $33.3M | $-116.7M | ||
| Q3 24 | $-1.6M | $-63.8M | ||
| Q2 24 | $1.2M | $-83.4M | ||
| Q1 24 | $410.0K | $-109.0M |
自由现金流率CFFIRXRX
| Q4 25 | 61.8% | -133.1% | ||
| Q3 25 | 63.0% | -2272.5% | ||
| Q2 25 | -13.6% | -413.9% | ||
| Q1 25 | 9.0% | -907.4% | ||
| Q4 24 | 103.8% | -2567.7% | ||
| Q3 24 | -4.9% | -244.6% | ||
| Q2 24 | 3.7% | -578.5% | ||
| Q1 24 | 1.3% | -789.9% |
资本支出强度CFFIRXRX
| Q4 25 | 6.5% | 3.5% | ||
| Q3 25 | 2.1% | 4.7% | ||
| Q2 25 | 1.6% | 16.4% | ||
| Q1 25 | 0.8% | 12.4% | ||
| Q4 24 | 10.9% | 28.6% | ||
| Q3 24 | 6.1% | 17.5% | ||
| Q2 24 | 1.7% | 8.2% | ||
| Q1 24 | 1.6% | 48.2% |
现金转化率CFFIRXRX
| Q4 25 | 3.65× | — | ||
| Q3 25 | 3.31× | — | ||
| Q2 25 | -0.57× | — | ||
| Q1 25 | 0.60× | — | ||
| Q4 24 | 6.09× | — | ||
| Q3 24 | 0.07× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.26× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CFFI
| Community Banking | $25.9M | 72% |
| Consumer Finance Segment | $7.0M | 19% |
| Mortgage Banking Segment | $1.9M | 5% |
| Other | $1.1M | 3% |
RXRX
暂无分部数据
